Apollon Formularies PLC (LON:APOL) Chairman and CEO Dr Stephen Barnhill, who also serves at Chairman at Aion Therapeutic Inc (CSE:AION) tells Proactive.
Breast Cancer Cells Through Multiple Pathways
LONDON/TORONTO, Apollon Formularies plc (AQSE: APOL, Apollon or the Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION, Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon s affiliate, Apollon Formularies Jamaica Limited ( Apollon Jamaica ), and the medicinal mushroom f
18 maggio 2021 17:32
Fonte: Adnkronos
#salute-e-benessere
LONDON and TORONTO, May 18, 2021 /PRNewswire/ Apollon Formularies plc (AQSE: APOL) ( Apollon or the Company ), a UK based international pharmaceutical company trading on the Aquis Stock Exchange, and Aion Therapeutic Inc. (CSE: AION) ( Aion ), a BC based international pharmaceutical company trading on the Canadian Securities Exchange, are pleased to announce that joint testing has revealed their combined formulations to be effective in killing HER2+ breast cancer cells grown in 3D cell culture via three separate mechanisms: direct cell cytotoxicity, immune stimulated T-cell cytotoxicity, and macrophage induced phagocytosis. HER2-positive constitutes approximately 20% of all breast cancers.
The testing was performed by BIOENSIS, an independent, pre-clinical predictive pharmaceutical testing laboratory. The medical cannabis formulations were developed by Apollon s affiliate, Apollon Formularies Jamaica Limited ( Ap
A glance at some of the day s highlights from the Proactive Investors US and Canada newswires Your daily round-up from the world of Proactive
Mydecine Innovations Group Inc (NEO:MYCO) (OTCMKTS:MYCOF) (FRA:0NFA) announced that it ended the first quarter of 2021 with cash and equivalents of C$11.3 million, which the company said will help it advance its intellectual property portfolio, build out its clinical trial calendar, expand its European operations and develop its technology division. As well, Mydecine said its strategic partnerships are expected to expand its drug development capabilities to more efficiently and rapidly lead the next generation of psychedelic-assisted therapeutics.